Exsulin Corp. releases clinical trial results for investigational diabetes drug
MINNEAPOLIS Results of a mid-stage clinical trial of a drug designed to restore the ability of the pancreas to produce insulin have appeared online in the journal Diabetes/Metabolism Research and Reviews, the drug’s manufacturer has announced.
Exsulin Corp. said it planned to move forward immediately on Exsulin (INGAP peptide), designed for use in patients with Type 1 and Type 2 diabetes.
“Since the landmark discovery of insulin in 1921, only incremental progress has been made in insulin therapy, which remains difficult and hazardous – particularly for people with [Type 1 diabetes],” Exsulin Corp. founder and chairman G. Alexander Fleming said in a statement. “These study results are very encouraging that Exsulin therapy could restore normal insulin secretion, which would allow insulin-dependent [Type 1 diabetes] and [Type 2 diabetes] patients to achieve normal glucose control while decreasing or ending their dependence on insulin treatment.”
Researchers discover ways to prevent infection of cells
MADISON, Wis. Researchers at the University of Wisconsin-Madison have found a way to block biological communications between cells that lead to viral infections and tumors.
In a study supported by grants from the National Institutes of Health and published online in the Proceedings of the National Academy of Sciences, a team of researchers from UW-Madison and other universities created a set of synthetic molecules that interacted with the HIV protein gp41 to prevent the infection of cells. Several viruses, including HIV, Ebola and influenza, use interactions between viral and cellular proteins to infect cells.
“There’s a lot of information transfer that occurs when proteins come together, and one would often like to block that information flow,” UW-Madison chemistry professor Samuel Gellman said in a statement.
While it remains unclear whether this method can be used to create anti-HIV drugs, Gellman said it did could potentially lead to new ways of thinking about designing antiviral drug molecules.
Behavioral Health Central to relaunch Web portal
CONSHOHOCKEN, Pa. In an effort to bring together clinicians, patients, payers, executives and administrators on one central Web portal, Behavioral Health Central is relaunching the www.BehavioralHealthCentral.com site.
The new Web portal provides industry and clinical news, resources and tools, and social networking capabilities designed to bring together all of the major stakeholders in behavioral healthcare.
“This new genesis of our site brings everyone to the table so they all have access to similar resources and information,” stated Jim Miller, president of BHC. “It’s a recognition that, in the end, we’re all striving for the same thing — better treatment pathways, leading to improved outcomes for patients.”
Another key feature of the new site is the addition of nationwide directories that allow professionals and consumers to quickly locate treatment facilities, therapists, vendors, drug information, association lists and more.